<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Diagnosis of the <z:e sem="disease" ids="C0178874" disease_type="Neoplastic Process" abbrv="">neoplastic progression</z:e> in <z:hpo ids='HP_0100580'>Barrett's esophagus</z:hpo> using the histologic classification of <z:mpath ids='MPATH_589'>dysplasia</z:mpath> is frequently difficult </plain></SENT>
<SENT sid="1" pm="."><plain>The <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> suppressor protein p53, when mutated, confers a promoter effect on cell growth </plain></SENT>
<SENT sid="2" pm="."><plain>The purpose of this study was to evaluate the applicability of p53 as an intermediate biomarker of <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">malignancy</z:e> in <z:hpo ids='HP_0100580'>Barrett's esophagus</z:hpo> </plain></SENT>
<SENT sid="3" pm="."><plain>Archival analysis of 100 biopsy specimens of <z:hpo ids='HP_0100580'>Barrett's esophagus</z:hpo> and 10 esophageal <z:mp ids='MP_0009308'>adenocarcinomas</z:mp> were compared with 35 <z:hpo ids='HP_0011010'>chronic</z:hpo> <z:hpo ids='HP_0100633'>esophagitis</z:hpo> biopsy specimens </plain></SENT>
<SENT sid="4" pm="."><plain>Immunocytochemistry using an anti-p53 monoclonal antibody was performed and elevated immunoreactivity quantitated microscopically </plain></SENT>
<SENT sid="5" pm="."><plain>Data were analyzed using a logistic regression model </plain></SENT>
<SENT sid="6" pm="."><plain>Significant p53 immunoreactivity occurred as follows: <z:hpo ids='HP_0011010'>chronic</z:hpo> <z:hpo ids='HP_0100633'>esophagitis</z:hpo> (0%), <z:hpo ids='HP_0100580'>Barrett's esophagus</z:hpo> without <z:mpath ids='MPATH_589'>dysplasia</z:mpath> (10%), with low-grade <z:mpath ids='MPATH_589'>dysplasia</z:mpath> (60%), with high-grade <z:mpath ids='MPATH_589'>dysplasia</z:mpath> (100%), and <z:mp ids='MP_0009308'>adenocarcinoma</z:mp> (70%) </plain></SENT>
<SENT sid="7" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> cases of <z:hpo ids='HP_0100580'>Barrett's esophagus</z:hpo> were significantly immunoreactive when compared with the <z:hpo ids='HP_0011010'>chronic</z:hpo> <z:hpo ids='HP_0100633'>esophagitis</z:hpo> cases (p = 0.001) </plain></SENT>
<SENT sid="8" pm="."><plain>There was an increase in p53 immunoreactivity as the histologic classification progressed toward <z:mp ids='MP_0009308'>adenocarcinoma</z:mp> (p = 0.001) </plain></SENT>
<SENT sid="9" pm="."><plain>Progression to high-grade <z:mpath ids='MPATH_589'>dysplasia</z:mpath> may be predicted based on p53 immunoreactivity </plain></SENT>
<SENT sid="10" pm="."><plain>These findings suggest a role for p53 as an intermediate biomarker in <z:hpo ids='HP_0100580'>Barrett's esophagus</z:hpo> </plain></SENT>
</text></document>